Hospital

A panel of neurology pharmacy specialists discusses the expanding clinical role of pharmacists in multiple sclerosis care.

Late-stage Lyme disease vaccine candidate VLA15 boosts immunization hopes as tick infections rise.

Tarlatamab, a DLL3 T‑cell engager, advances treatment of extensive‑stage SCLC.

Insights from the 2026 HOPA Annual Conference highlight the pharmacist's role in operationalizing belantamab mafodotin.

The indication is for patients who have received 1 to 3 prior systemic treatment regimens, of which at least 1 includes bevacizumab.

Albuminuria (uACR) flags early vascular damage linking chronic kidney disease and cardiovascular risk.

A new 2026 American Heart Association study shows COVID-19 infection sharply raises heart attack risk, whereas vaccination appears safe—key guidance for patient counseling.

Pharmacists play a key role in modern obesity care through education, access support, and collaboration.

Long-acting HIV injections and twice-yearly PrEP reshape care, while pharmacists tackle stigma, insurance hurdles, and adherence to close access gaps.

Swapping 30 minutes of teen sedentary time for vigorous activity or extra sleep cuts insulin resistance by 15%, aiding type 2 diabetes (T2D) prevention.

Joseph Saseen, PharmD, breaks down how the new PREVENT ASCVD calculator improves on its predecessor and what the expanded LDL-C goal framework means for treatment decisions in pharmacy practice.

Case reports show that alternative agents, including phenytoin, have been successful in resolving digoxin-induced arrhythmias.

Emerging therapies, AI, and patient-centered approaches are reshaping cardiovascular pharmacy.

This week's episode covers the court ruling halting RFK Jr.'s childhood vaccine schedule changes, the FDA's RSV vaccine approval for adults aged 18–49, pharmacist-led GLP-1 optimization strategies, and new gabapentin data in SUD treatment settings.

FDA approves nivolumab with AVD for stage III/IV classical Hodgkin lymphoma, boosting PFS and redefining first-line care.

Learn why uACR screening flags early vascular damage linking chronic kidney disease and cardiovascular health.

Artificial intelligence is emerging as a vital tool for pharmacists in cardiovascular care—supporting clinical decisions, patient education, and adherence while maintaining guideline alignment.

The FDA approval of the Wegovy pill offers a new, effective GLP-1 option for weight management, with pharmacists playing a key role in patient counseling and adherence support.

The expanded indication is supported by findings from the phase 3 TRANSCEND clinical trial.

How pharmacists enter sports medicine, guide safe supplements, prevent doping risks, and join athlete care teams through the Sports Pharmacy Network.

Respiratory syncytial virus hits older adults hard and is often missed. Learn symptoms, testing, and how new vaccines and pharmacists help prevent severe illness.

In patients with diabetes, liver stiffness testing flags hidden MASLD fibrosis and sharply higher death risk.

Evidence questions anemia plus thrombocytopenia prognosis in primary myelofibrosis, helping oncology pharmacists refine hematology risk stratification.

Research suggests a shift from the Cockcroft-Gault formula to race-free eGFR testing to improve kidney function assessment and medication dosing.

Tucatinib triplet regimen with trastuzumab and capecitabine boosts survival and cerebrospinal fluid control in HER2-positive breast cancer leptomeningeal metastasis.